News

The FDA has given the novel agent NVL-655 a breakthrough therapy designation for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.

TNO155 combined with either spartalizumab or ribociclib showed acceptable safety and tolerability across solid tumors in a phase 1b open-label study.

The FDA accelerated approval of tarlatamab makes it the first bispecific T-cell engager therapy for a major solid tumor.

Nazli Dizman, MD, discusses her research on adherence to the American Society of Clinical Oncology Language of Respect Guidelines among patients with renal cell carcinoma.

Halle Moore, MD, discusses some of the main concerns that patients with breast cancer have about fertility after treatment.

Findings from a phase 1b/2 study support the continued development of palazestrant plus ribociclib for patients with estrogen receptor-positive/HER2-negative metastatic breast cancer.

According to a recent analysis, preliminary circulating tumor DNA kinetics could serve as an early pharmacodynamic biomarker, offering potential for early biologic proof of concept.

Lisocabtagene maraleucel has been granted FDA approval for the treatment of patients with relapsed/refractory follicular lymphoma.

The FDA has approved one of the first human papillomavirus self-collection solutions for use in the US.

In a phase 1/2 trial of NT219 with cetuximab in patients with squamous cell carcinoma of the head and neck, safety and tolerability responses were encouraging.

Phase 1 of the Acclaim-3 study evaluating quaratusugene ozeplasmid plus atezolizumab in patients with extensive-stage small cell lung cancer has enrolled and dosed its first patient.

Targeted Oncology spoke with Howard D. Edington, MD, about the advancements in engineering oncolytic viruses to be able to target specific cancers and various combination therapies with the novel treatment.

In this episode of Targeted Talks, Nini Wu, MD, MBA, shares her insights on the ever-changing world of technology in community oncology.

For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.

Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with chronic lymphocytic leukemia.

Decentralized clinical trials represent a promising approach to clinical research that can improve patient access to new treatments while streamlining the development process.

With the FDA clearance of an investigational new drug application for SynKIR-310, a phase 1 trial evaluating the agent in relapsed/refractory B-cell non-Hodgkin lymphomas will begin.

The phase 2 VERSATILE-002 trial evaluating Versamune HPV with pembrolizumab met its primary end point in patients with first-line recurrent metastatic head and neck squamous cell cancer.

Ariel Lopez-Chavez, MD, emphasizes the critical need for improved second-line therapies in small cell lung cancer.

The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.

A US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift care from reactive to preventive, easing strain on systems.

SNB-101, a nanoparticle drug for small cell lung cancer, received a fast track designation from the FDA for expedited development and review.

Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.

In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.

Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.

A BLA for subcutaneous nivolumab in solid tumors, lenvatinib becoming primary treatment in thyroid cancer, and expert discussions on IO/TKI combos in RCC. We also cover positive results from acalabrutinib combination in MCL and pembrolizumab combination in HER2-positive gastric cancer.

Due to federal budget constraints, the National Cancer Institute faces significant risk, impacting cancer research funding amid crucial breakthroughs.

The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.

Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE trial.

A study found that treatment with HEPZATO KIT showed a promising response rate of 36.3% for patients with unresectable metastatic uveal melanoma.